Expression of the β chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies

Neuropathology and Applied Neurobiology

Volumn 31, Issue 1, 2005, Pages 70-79

  Civatte, M ^a   Bartoli, C ^a   Schleinitz, N ^b   Chetaille, B ^b   Pellissier, J F ^b   Figarella Branger, D ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Chemokines; Inflammatory myopathies; Receptors

Indexed keywords

BETA CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; INFLAMMATORY EXUDATE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; ENDOTHELIUM CELL; EXUDATE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IDIOPATHIC INFLAMMATORY MYOPATHY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; INFLAMMATORY CELL; MACROPHAGE; MALE; MUSCLE FIBER MEMBRANE CONDUCTANCE; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPORADIC INCLUSION BODY MYOSITIS;

ADOLESCENT; ADULT; AGED; CHEMOKINES, CC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 13544269244     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2004.00591.x     Document Type: Article

References (43)

1. Engel AG, Banker BQ. The polymyositis and dermatomyositis syndromes. In Myology. Eds AG Engel, C Franzini-Armstrong. New York: McGrauw Hill, 1994; 1335-89
2. Griggs R, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Lewis PR. Inclusion body myositis and myopathies. Ann Neural 1995; 38: 705-13
3. Hohlfeld R. Polymyositis and dermatomyositis. In Structural and Molecular Basis of Skeletal Muscle Disease. Ed. G Karpati. Basel: ISN Neuropathol Press, 2002; 221-7
4. Karpati G, Carpenter S. Pathology of Inflammatory Myopathies. In Balliere's Clinical Neurology: Inflammatory Myopathies. Ed. FL Mastaglia, London: Balliere Timdall, 1993; vol 2: 527-56
5. Rider LG, Miller FW. Idiopathic inflammatory muscle disease: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 37-54
6. Dalakas MC. The molecular and cellular pathology of inflammatory muscle diseases. Curr Op Pharmacol 2001; 1: 300-6
7. Mantegazza R, Bernasconi P, Confalonieri P, Cornelio F. Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. J Neurol 1997; 244: 277-87
8. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986; 17: 704-21
9. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314: 329-34
10. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209-15
11. Figarella-Branger D, Lacroix C, Coquet M, Gherardi R, Pellissier JF. Myopathies inflammatoires idiopathiques. Ann Pathol 2001; 21: 279-84
12. Figarella-Branger D, Pellissier JF, Bianco N, Devictor B, Toga M. Inflammatory and non-inflammatory inclusion body myositis. Characterization of the mononuclear cells and expression of the immunoreactive class I major histocompatibility complex product. Acta Neuropathol (Berl) 1990; 79: 528-36
13. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988; 23: 64-72
14. Askanas V, Engel WK. Inclusion-body myositis. newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 1-14
15. Oldfors A, Fyhr IM. Inclusion body myositis: genetic factors, aberrant protein expression, and autoimmunity. Curr Opin Rheumatol 2001; 13: 469-75
16. De Bleecker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. Neuropathol Exp Neurol 1994; 53: 369-76
17. Liprandi A, Figarella-Branger D, Daniel L, Lepidi H, Bartoli C, Pellissier JF. Expression of adhesion molecules in idiopathic inflammatory myopathies. Immunohistochemical study of 17 cases. Ann Pathol 1999; 19: 12-8
18. Loetscher P, Seitz M, Baggiolini M, Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996; 184: 569-77
19. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-45
20. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002; 283: R7-28
21. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev 2001; 12: 313-35
22. Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF. Cytokines, chemokines and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003; 28: 659-82
23. Confalonieri P, Bernasconi P, Megna P, Galbiati S, Cornelio F, Mantegazza R. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 2000; 59: 164-9
24. De Bleecker J, De Paepe B, Vanwalleghem I, Schroder J. Differential expression of chemokines in inflammatory myopathies. Neurology 2002; 58: 1779-85
25. Liprandi A, Bartoli C, Figarella-Branger D, Pellissier JF, Lepidi H. Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol (Berl) 1999; 97: 642-8
26. Bartoli C, Civatte M, Pellissier JF, Figarella-Branger D. CCR2A and CCR2B, the two isoforms of the monocyte chemoattractant protein-1 receptor are up-regulated and expressed by different cell subsets in idiopathic inflammatory myopathies. Acta Neuropathol (Berl) 2001; 102: 385-92
27. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 13: 344-7
28. Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK. The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5′-end heterogeneity, dual promoteur usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. J Biol Chem 1997; 272: 30662-71
29. De Rossi M, Bernasconi P, Baggi F, de Waal Malefyt R, Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 2000; 12: 1329-35
30. Nagaraju K. Update on immunopathogenesis in inflammatory myopathies. Curr Opin Rheumatol 2001; 13: 461-8
31. Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998; 113: 407-14
32. Adams EM, Kirkley J, Eidelman G, Dohlman J, Plotz PH. The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 1997; 109: 275-85
33. Johnson-Leger C, Aurrand-Lions M, Imhof BA. The parting of the endothelium: miracle, or simply a junctional affair? J Cell Scii 2000; 113: 921-33
34. De Bleecker J, De Paepe B, Racz G, Schroeder JM. Beta chemokines and their receptors in inflammatory myopathies. J Neurol Sci 2002; 199: S4
35. De Bleecker JL, Engel AG. Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. Am J Pathol 1995; 146: 1178-87
36. Gomez-Reino JJ, Pablos JL, Carreira PE, Santiago B, Serrano L, Vicario JL, Balsa A, Figueroa M, de Juan MD. Association of rheumatoid arthritis with a functional chemokine receptor. CCR5. Arthritis Rheum 1999; 42: 989-92
37. Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998; 24: 73-9
38. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 865-74
39. Tews DS, Goebel HH. Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol 1995; 59: 185-94
40. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM. CCR5 is characteristic of Th1 lymphocytes. Nature 1998; 391: 344-5
41. Patterson BK, Czerniewski M, Andersson J, Sullivan Y, Su F, Jiyamapa D, Burki Z, Landay A. Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: CCR 5 expression is downregulated by IL-10 in CD4-positive lymphocytes. Clin Immunol 1999; 91: 254-62
42. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997; 277: 2005-7
43. Jinquan T, Quan S, Feili G, Larsen CG, Thestrup-Pedersen K. Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4. J Immunol 1999; 162: 4285-92